A Phase III Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Details
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years
Eligibility
You can join if...
You have been diagnosed with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and have previously received at least one treatment that may include a BTK inhibitor for your disease and:
did not respond to that treatment, or
initially responded but your CLL/CLL later progressed on that treatment, or;
experienced side effects that made it difficult to continue that treatment or
the decision to stop that treatment was made by you and your study doctor